Fas/FasL Antagonist, Kp7-6-Calbiochem

C₄₈H₅₆N₁₀O₁₅S₂

1077.15

An exocyclic cysteine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (K_d = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.
An exocyclic cystine-knot peptide that specifically antagonizes Fas/FasL-mediated cellular apoptotic signals (58% reduction of FasL-induced apoptosis in Jurkat cells at 1 mg/ml). Binds to FasL (Cat. Nos. PF033 and PF092) and Fas (CD95/APO-1) with comparable affinity (K_d = 11.2 & 13.2 µM, respectively), resulting in disabled receptor ensembles and altered signaling pathways. Shown to prevent Con A (Cat. No. 234567)-induced liver injury in a murine hepatitis model in vivo. Does not bind to TNF-α or TNFR.

Product does not compete with ATP.
Primary Target
Fas/FasL-mediated cellular apoptotic signals
Kd = 11.2 & 13.2 µM for FasL and Fas (CD95/APO-1), respectively
Reversible: no
Cell permeable: no

Toxicity: Standard Handling (A)

H₂N-Tyr-Cys*-Asp-Glu-His-Phe-Cys*-Tyr-CO₂H, Cyclic [disulfide bond between Cys-Cys]

Supplied as a trifluoroacetate salt.

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Carmona, E.M., et al. 2006. J. Immunol.177, 459.
Hasegawa, A., et al. 2004. Proc. Natl. Acad. Sci. USA101, 6599.

Sold under license of U.S. Patent 7,288,519.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥98% (HPLC)

lyophilized powder

Calbiochem^®

OK to freeze
desiccated (hygroscopic)
protect from light

white

DMSO: 5 mg/mL

ambient

2-8℃

25 mg in Plastic ampoule
Packaged under inert gas

11 - Combustible Solids

WGK 1